Director Jason Rhodes resigns from Replimune Board to focus on Atlas Venture commitments

Replimune Group, Inc.

Jason Rhodes, partner at Atlas Venture, resigned from Replimune's Board effective May 31, 2022.
Rhodes served on the Board since 2015, when Atlas led Replimune's Series A financing.
Resignation not due to any dispute; Rhodes cited growing commitments at Atlas, including new fund launch in March 2022.
CEO Philip Astley-Sparke thanked Rhodes and Atlas for their capital formation and company-building support.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jason Rhodes

director

REPL · Replimune Group, Inc.

Effective: 2022-05-31
Filed: June 3, 2022, 7:59 PM ET

On May 31, 2022, Jason Rhodes, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board of his decision to resign as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jason Rhodes resigned as director at Replimune Group, Inc..

Action: resigned
Role: director

Exact text from the filing

On May 31, 2022, Jason Rhodes, a member of the Board of Directors (the “Board”) of Replimune Group, Inc. (the “Company”), notified the Board of his decision to resign as a director of the Company, effective immediately.

View on SEC.gov

Replimune Group, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-067870

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.